Fig. 2From: Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutationEvaluation of eight MET-TKIs, including four candidates, against clones with MET D1228X or Y1230X. A The IC50 values (nM) of each drug for Ba/F3 cells harboring METex14 plus the indicated MET secondary mutations are expressed according to the indicated color scale. * indicates Ba/F3 clones generated using the corresponding vectors. Other cell lines were derived by ENU mutagenesis. Growth inhibition curves are summarized in Additional file 2: Fig. S2A and B. B The IC50 values of each drug for cells with each secondary mutation are expressed as fold increases of the IC50 for parental cells with METex14 in dot plots. C Western blot analyses of Ba/F3 cells with METex14 with/without secondary mutations treated with MET-TKIs at the indicated concentrations for 3Â h. D The sensitivity index (SI) was defined as the IC50 value divided by the concentration max (Cmax) of each drug, which was reported in a clinical study. SI is expressed in a heatmap by the indicated color scales. For cabozantinib, since no PK data at 60Â mg/day were available, the values were estimated from those reported at 80Â mg/day and 40Â mg/day based on previous reports (Kuzrock, R. et al. J Clin Oncol. 2011)Back to article page